London
· Delayed Price · Currency is GBP · Price in DKK ChemoMetec Statistics
Total Valuation
ChemoMetec has a market cap or net worth of GBP 958.41 million. The enterprise value is 928.93 million.
| Market Cap | 958.41M |
| Enterprise Value | 928.93M |
Important Dates
The next estimated earnings date is Wednesday, May 7, 2025.
| Earnings Date | May 7, 2025 |
| Ex-Dividend Date | Oct 11, 2024 |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | -0.13% |
| Shares Change (QoQ) | +0.09% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 17.34M |
Valuation Ratios
The trailing PE ratio is 51.12.
| PE Ratio | 51.12 |
| Forward PE | n/a |
| PS Ratio | 18.81 |
| PB Ratio | 14.45 |
| P/TBV Ratio | 18.60 |
| P/FCF Ratio | 56.80 |
| P/OCF Ratio | 49.05 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 36.80, with an EV/FCF ratio of 55.05.
| EV / Earnings | 49.55 |
| EV / Sales | 17.62 |
| EV / EBITDA | 36.80 |
| EV / EBIT | 38.49 |
| EV / FCF | 55.05 |
Financial Position
The company has a current ratio of 4.00, with a Debt / Equity ratio of 0.01.
| Current Ratio | 4.00 |
| Quick Ratio | 2.88 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | 0.04 |
| Debt / FCF | 0.05 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is 30.83% and return on invested capital (ROIC) is 23.68%.
| Return on Equity (ROE) | 30.83% |
| Return on Assets (ROA) | 19.86% |
| Return on Invested Capital (ROIC) | 23.68% |
| Return on Capital Employed (ROCE) | 34.62% |
| Revenue Per Employee | 276,943 |
| Profits Per Employee | 101,896 |
| Employee Count | 174 |
| Asset Turnover | 0.69 |
| Inventory Turnover | 0.33 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +67.67% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +67.67% |
| 50-Day Moving Average | 529.80 |
| 200-Day Moving Average | 458.83 |
| Relative Strength Index (RSI) | 48.00 |
| Average Volume (20 Days) | 3,850 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, ChemoMetec had revenue of GBP 50.96 million and earned 18.75 million in profits. Earnings per share was 1.08.
| Revenue | 50.96M |
| Gross Profit | 46.41M |
| Operating Income | 23.32M |
| Pretax Income | 24.44M |
| Net Income | 18.75M |
| EBITDA | 24.39M |
| EBIT | 23.32M |
| Earnings Per Share (EPS) | 1.08 |
Balance Sheet
The company has 29.36 million in cash and 862,368 in debt, giving a net cash position of 28.49 million.
| Cash & Cash Equivalents | 29.36M |
| Total Debt | 862,368 |
| Net Cash | 28.49M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 66.31M |
| Book Value Per Share | 3.81 |
| Working Capital | 40.83M |
Cash Flow
In the last 12 months, operating cash flow was 19.54 million and capital expenditures -2.67 million, giving a free cash flow of 16.87 million.
| Operating Cash Flow | 19.54M |
| Capital Expenditures | -2.67M |
| Free Cash Flow | 16.87M |
| FCF Per Share | n/a |
Margins
Gross margin is 91.07%, with operating and profit margins of 45.77% and 36.79%.
| Gross Margin | 91.07% |
| Operating Margin | 45.77% |
| Pretax Margin | 47.96% |
| Profit Margin | 36.79% |
| EBITDA Margin | 47.87% |
| EBIT Margin | 45.77% |
| FCF Margin | 33.11% |
Dividends & Yields
This stock pays an annual dividend of 0.45, which amounts to a dividend yield of 0.09%.
| Dividend Per Share | 0.45 |
| Dividend Yield | 0.09% |
| Dividend Growth (YoY) | -35.48% |
| Years of Dividend Growth | n/a |
| Payout Ratio | 41.16% |
| Buyback Yield | 0.13% |
| Shareholder Yield | 0.23% |
| Earnings Yield | 1.96% |
| FCF Yield | 1.76% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
ChemoMetec has an Altman Z-Score of 34.57.
| Altman Z-Score | 34.57 |
| Piotroski F-Score | n/a |